Abdulraheem Yacoub
YOU?
Author Swipe
View article: RESULTS FROM VERIFY, A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF RUSFERTIDE FOR THE TREATMENT OF POLYCYTHEMIA VERA
RESULTS FROM VERIFY, A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF RUSFERTIDE FOR THE TREATMENT OF POLYCYTHEMIA VERA Open
View article: Real-world analysis of polycythemia vera treatment reveals nonadherence to NCCN guidelines in a large proportion of patients
Real-world analysis of polycythemia vera treatment reveals nonadherence to NCCN guidelines in a large proportion of patients Open
View article: Final safety and efficacy results from a phase 1/2 study of tagraxofusp, a CD123-targeted therapy, for myelofibrosis
Final safety and efficacy results from a phase 1/2 study of tagraxofusp, a CD123-targeted therapy, for myelofibrosis Open
Patients with myelofibrosis (MF) who are resistant to or relapse after Janus kinase inhibitor (JAKi) therapy have limited treatment options and typically poor prognoses. CD123 is overexpressed in various myeloid malignancies, including MF.…
View article: Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients Aged 65 Years and Above With Myelofibrosis
Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients Aged 65 Years and Above With Myelofibrosis Open
In myelofibrosis patients aged 65 years and above undergoing allogeneic HCT, a favorable 2-year overall survival of 62% was noted with an inferior DFS compared to younger patients, while other post-transplant outcomes remained comparable. …
View article: Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms
Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms Open
View article: Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study
Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study Open
View article: A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial
A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial Open
No new drugs have been approved for essential thrombocythemia (ET) treatment since the anagrelide approval in 1997. Ropeginterferon alfa-2b-njft (ropeg) is approved for polycythemia vera, providing a rationale for its use in ET. Its curren…
View article: Navigating the peginterferon Alfa-2a shortage: practical guidance on transitioning patients to ropeginterferon alfa-2b
Navigating the peginterferon Alfa-2a shortage: practical guidance on transitioning patients to ropeginterferon alfa-2b Open
View article: PARADIGM-PV: a randomized, multicenter phase 4 study to assess the efficacy and safety of ropeginterferon alfa-2b in patients with low- or high-risk polycythemia vera
PARADIGM-PV: a randomized, multicenter phase 4 study to assess the efficacy and safety of ropeginterferon alfa-2b in patients with low- or high-risk polycythemia vera Open
View article: Supplementary Table S1 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Table S1 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Clinical info on the platelets-responsive and non-responsive patients
View article: Supplementary Figure S8 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S8 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
AVID200 induced similar decrements in the plasma levels of TGF-β in the three patients with and without platelet response
View article: Supplementary Table S3 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Table S3 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Representativeness of Study Participants.
View article: Supplementary Figure S7 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S7 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Effects of AVID200 therapy on plasma TGFβ levels.
View article: Supplementary Figure S1 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S1 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
MPN-RC 118 phase 1b study schema
View article: Supplementary Figure S3 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S3 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Duration of treatment and response status.
View article: Supplementary Figure S2 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S2 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Baseline mutational profile of enrolled patients.
View article: Supplementary Table S2 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Table S2 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Patient listing of prior myelofibrosis treatment and time since discontinuation if known
View article: Supplementary Figure S9 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S9 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
PK data for Cycle 1 (first 24 hours only) for A) 180 mg/m2 dose level and B) 550 mg/m2 dose level during dose escalation phase I.
View article: Supplementary Table S1 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Table S1 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Clinical info on the platelets-responsive and non-responsive patients
View article: Supplementary Figure S4 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S4 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Oncoprint Analysis of Serial Samples from Phase 1b Trial of AVID200
View article: Supplementary Figure S2 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S2 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Baseline mutational profile of enrolled patients.
View article: Supplementary Figure S9 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S9 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
PK data for Cycle 1 (first 24 hours only) for A) 180 mg/m2 dose level and B) 550 mg/m2 dose level during dose escalation phase I.
View article: Supplementary Table S3 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Table S3 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Representativeness of Study Participants.
View article: Supplementary Table S4 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Table S4 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Individual patient data for AUC, Cmax and Tmax for dose levels 1 and 2 (Lot A). Summary measures for DL 1 and DL2 are shown in red.
View article: Supplementary Table S4 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Table S4 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Individual patient data for AUC, Cmax and Tmax for dose levels 1 and 2 (Lot A). Summary measures for DL 1 and DL2 are shown in red.
View article: Supplementary Figure S6 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S6 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
GATA1 expression in megakaryocytes from patients treated with AVID200
View article: Supplementary Figure S3 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S3 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Duration of treatment and response status.
View article: Data from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Data from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Purpose: Myelofibrosis (MF) is a clonal myeloproliferative neoplasm characterized by systemic symptoms, cytopenias, organomegaly, and bone marrow fibrosis. JAK2 inhibitors afford symptom and spleen burden reduction but do not alter the dis…
View article: Supplementary Figure S5 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S5 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
The bone marrow from patients with MF contain more CD42pos cells than patients with ET or with hematopoietic malignancies without fibrosis (normal control).
View article: Supplementary Figure S8 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S8 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
AVID200 induced similar decrements in the plasma levels of TGF-β in the three patients with and without platelet response